## EXPRESS MAIL CERTIFICATE

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

Typed or Printed Name Dave Glisson Express Mail No. EL563650187US

Signature Dave Slisson Date June 23, 2000

## CERTIFICATION REGARDING SEQUENCE LISTING

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

Attorney Docket	SHIM-006		
First Named Inventor	Takuva Tamatani et al.		
Application Number	To be Assigned		
Int'l Filing Date	16 DEC 1998		
Group Art Unit	To be Assigned		
Examiner Name	To be Assigned		
Title	Monoclonal Antibody Against Connective Tissue Growth Factor and Medicinal Uses Thereof		

Sir:

I hereby certify that the enclosed Sequence Listing is being submitted in paper copy and on a computer-readable diskette, and that the content of the paper and computer readable copies are the same.

I hereby also certify that the enclosed submission includes no new matter.

Applicants believe that no fee is due in connection with the filing of this paper. However, the Commissioner is hereby authorized to charge any fees which may be required by this paper, or to credit any overpayment, to Deposit Account No. 50-0815.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date:

BOZICEVIC, FIELD & FRANCIS LLP

200 Middlefield Road, Suite 200

Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

/Karl Bozicevic /

Registration No. 28,807

	APF	PLICANT(S) FOR DO/EO/US Takuya TAMATANI, Katsunari TEZUKA, Shinji SAKAMOTO and Masaharu TAKIGAWA
	App 1.	olicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:  X This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
	2.	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
this first time first this	3.	X This express request to begin examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).
	4.	X A proper Demand for International Preliminary Examination was made by the 19 <sup>th</sup> month from the earliest claimed priority date.
H der for free	5.	<ul> <li>X A copy of the International Application as filed (35 U.S.C. 371(c)(2)):</li> <li>a is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>bX has been transmitted by the International Bureau. (However, a courtesy copy is attached hereto.)</li> <li>c is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ul>
	6.	X A translation of the International Application into English (35 U.S.C. 371(c)(2)).
	7.	Amendments to the claims of the International Application under PCT Article 19 (37 U.S.C. 371(c)(3)):  a are transmitted herewith (required only if not transmitted by the International Bureau).  b have been transmitted by the International Bureau.  c have not been made; however, the time limit for making such amendments has NOT expired.  dX have not been made and will not be made.
	8.	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
	9.	X An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (UNSIGNED)
	10.	A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 16 below concern other document(s) or information included:

A SECOND or SUBSEQUENT preliminary amendment.

A change of power of attorney and/or address letter.

- Diskette and Paper Copy of Sequence Listing

X A FIRST preliminary amendment.

- Certification of Sequence Listing

A substitute specification.

X Other items or information:

- Return Postcard

An Information Disclosure Statement under 37 CFR 1.97 and 1.98.

the date indicated below and is addressed to the Assistant Commissioner for Patents, Washington, D.C.

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

AND MEDICINAL USES THEREOF

Dave Glisson

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

1th the United States Postal Service "Express Mail Post Offic

INTERNATIONAL FILING DATE

MONOCLONAL ANTIBODY AGAINST CONNECTIVE TISSUE GROWTH FACTOR

An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.

16 DEC 98

Express Mail No.

Date

EXPRESS MAIL CERTIFICATE

**Typed or Printed Name** 

Signature

Form PTO-1390 (REV 10-94)

PCT/JP98/05697

11.

12.

13.

14.

15.

16.

TITLE OF INVENTION

I hereby certify that this paper or fee is being depos

INTERNATIONAL APPLICATION NO.



idressee" service under 37 C.F.R. § 1.10 on

EL569650187US

PRIORITY DATE CLAIMED

ATTORNEY'S DOCKET NUMBER

June 23, 2000

SHIM-006

To be Assigned

25 DEC 97

	700 NG(	CIPCLIFIC 23 JUN
U.S. APPLICATION NO. (If known see 37	INTERNATIONAL APPLICATION NO PCT/JP98/05697	TTORNEY'S DOCKET NUMBER HIM-006
17. X The following fees are submitted:		

17. X The following fees are submitted:

Basic National Fee (37 CFR 1.492(a)(1)-(5)):

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and international search report not prepared by the EPO or JPO \$970.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search report prepared by the EPO or JPO

\$840.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$ 96.00

ENTER APPROPRIATE BASIC FEE AMOUNT =  Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	840.00	
				\$	0	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE			
Fotal Claims	21 - 20 =	1	X \$18.00	\$	18.00	
ndependent Claims	8 - 3=	5	X \$78.00	\$	390.00	,
MULTIPLE DEPENDENT	CLAIM(S) (if applicable)		+ \$260.00	\$		
TOTAL OF ABOVE CALCULATIONS =				\$	1248.00	
Reduction of ½ for filing by small entity, if applicable. A Small Entity Statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28)				s	0	
SUBTOTAL =				\$	1248.00	
Processing Fee of \$130.00 for furnishing the English translation later than2030 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	0	
TOTAL NATIONAL FEE =				s	1248.00	<u> </u>
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.				\$	0	
TOTAL FEES ENCLOSED =				\$	1248.00	
					Amount to be: refunded	\$
<del>-</del>					charged	\$ 1248.00

1	A check in the amount of \$	to cover the above fees is included.
L	The check in the unionit of $\phi_{}$	_ to cover the above rees is included

b... X Please charge my Deposit Account No. 50-0815 in the amount of \$1248.00 to cover the above fees.

c... X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0815.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a setition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025 (650) 327-3400 Telephone SIGNATURE

Karl Bozicevic Reg. No. 28,807